Corvus Pharmaceuticals (NASDAQ:CRVS) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a research report released on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $11.00 price target on the stock. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2024 earnings at ($0.12) EPS and FY2029 earnings at $0.49 EPS.

A number of other equities analysts also recently commented on CRVS. LADENBURG THALM/SH SH raised their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Oppenheimer upped their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Finally, Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

Shares of NASDAQ CRVS opened at $5.83 on Thursday. Corvus Pharmaceuticals has a one year low of $1.30 and a one year high of $10.00. The business has a fifty day simple moving average of $7.67 and a 200 day simple moving average of $5.29. The firm has a market capitalization of $374.62 million, a price-to-earnings ratio of -6.27 and a beta of 1.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Samlyn Capital LLC lifted its stake in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after acquiring an additional 3,774,658 shares during the period. Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $10,855,000. Geode Capital Management LLC boosted its stake in shares of Corvus Pharmaceuticals by 22.4% in the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after purchasing an additional 102,869 shares during the last quarter. State Street Corp grew its position in shares of Corvus Pharmaceuticals by 48.2% during the 3rd quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after buying an additional 57,943 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares during the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.